Imaging and SLN Biopsy for Patients With Melanoma

Panelists: Robert H. I. Andtbacka, MD, CM, Huntsman; Omid Hamid, MD, The Angeles Clinic; Merrick I. Ross, MD, MD Anderson; Jeffrey A. Sosman, MD, Vanderbilt; Mario Sznol, MD, Yale;
Jeffrey S. Weber, MD, PhD, Moffitt
Published Online: Tuesday, July 1, 2014
For High-Definition, Click
A variety of imaging techniques can be utilized for determining the extent of disease in patients with melanoma, including PET-CT scans and MRI. The exact patient population that is ideal for imaging can be guided by patient and tumor characteristics, such as tumor thickness and the presences of symptoms.

In asymptomatic patients, routine imaging by PET or CT scans may result in a higher rate of false positives than actual positives, believes Merrick I. Ross, MD. However, if a positive sentinel lymph node (SLN) is detected in a patient with a thick tumor, these approaches gain more value. Moreover, if the patient is a candidate for adjuvant therapy, an MRI or PET-CT scans could be useful for examining if CNS metastases are present, notes Ross.

In general, the imaging used should be risk adjusted, believes Jeffrey S. Weber, MD, PhD. Patients with stage IIIb/c or resected stage IV melanoma should be staged using a PET-CT scan and an MRI of the brain and spinal cord, since this could change the treatment administered. Discovering metastatic disease early may boost survival, Ross suggests. Making these types of imaging and SLN biopsy more important. However, Weber points out, the gains in survival with these techniques are modest, which begs the question of whether the additional costs of screening are justified in all patients.

At this point, a reliable biomarker does not exist for knowing which patients should receive SLN biopsy, PET-CT, or MRI. However, if a biopsy is conducted, a positive SLN can provide clues about the patient's outcome and risk, notes Jeffrey A. Sosman, MD. Additionally, a SLN biopsy that returns negative can be very reassuring to patients. To help further answer this question, the MSLT-II trial is comparing observation to surgery for patients with SLN-positive melanoma.
View More From This Discussion
Episode 1 Introduction: Surgical Excision of Melanoma
Episode 2 Imaging and SLN Biopsy for Patients With Melanoma
Episode 3 Lymph Node Management in Melanoma
Episode 4 Molecular Testing in Resectable Melanoma
Episode 5 Role of Adjuvant Radiation Therapy in Melanoma
Episode 6 Adjuvant Therapy for Stage III Melanoma
Episode 7 Adjuvant Treatment Selection in High-Risk Melanoma
Episode 8 Ipilimumab Side Effect Management in Melanoma
Episode 9 Strategies for the Detection of Recurrent Melanoma
Episode 10 Novel Therapies in Metastatic Melanoma
Episode 11 Immunotherapy Combinations in Advanced Melanoma
Episode 12 Nivolumab Plus Ipilimumab in Advanced Melanoma
Episode 13 Surgery Following Systemic Therapy in Melanoma
Episode 14 Conclusion: Improving Outcomes in Melanoma
Expert Panelists
Dr Mario Sznol

Mario Sznol, MD

Professor of Medical Oncology,
Clinical Research Program Leader,
Melanoma Program, Yale Cancer Center
Co-Director of Yale SPORE in Skin Cancer

Robert H. I. Andtbacka, MD, CM

Associate Professor, Surgical Oncology Department of Surgery, 
University of Utah Huntsman Cancer Institute 

Omid Hamid, MD

Chief, Translational Research/Immunotherapy, Director, Melanoma Program, 
The Angeles Clinic and Research Institute

Merrick I. Ross, MD

Professor of Surgery, Chief, Melanoma Section, MD Anderson Cancer Center

Jeffrey A. Sosman, MD

Professor of Medicine, Director, Melanoma & Tumor Immunotherapy Program, Co-Leader, Signal Transduction & Cell Proliferation Research Program, Medical Oncologist,
Vanderbilt University

Jeffrey S. Weber, MD, PhD

Director, Donald A. Adam Comprehensive Melanoma Research Center,
H. Lee Moffitt Cancer Center and Research Institute

Online CME Activities
Free CME from PER
PARP Inhibitors: Current and Future Options for Breast and Ovarian Cancer
Rapid Summaries and Commentaries: Update from Chicago - Advances in the Treatment of Lung Cancer
Medical Crossfire®: The JAK-STAT Pathway as a Mediator of Onco-Inflammation
2nd Annual Miami Lung Cancer Conference™ Medical Crossfire® Case Discussion
The content contained in this video is for general information purposes only. The viewer is encouraged to confirm the information presented with other sources. OncLiveTV Peer Exchange makes no representations or warranties of any kind about the completeness, accuracy, timeliness, reliability, or suitability of any of the information, including content or advertisements, contained in this video and expressly disclaims liability for any errors and omissions that may be presented in this video. OncLiveTV Peer Exchange reserves the right to alter or correct any error or omission in the information it provides in this video, without any obligations. OncLiveTV Peer Exchange further disclaims any and all liability for any direct, indirect, consequential, special, exemplary, or other damages arising from the use or misuse of any material or information presented in this video. The views expressed in this video are those of the panelists and do not necessarily reflect the opinion or policy of OncLiveTV Peer Exchange.
More Reading